World Leader in Production of Omega-3 Fatty Acids Launches Triomega(R) Brand Supplements in the U.S.

- Triomega(R) Provides Valuable Health Benefits to Heart, Mind and Joints -

OSLO, Norway and WALTHAM, Mass., March 23 -- Norway's Pronova Biocare, the world leader in the production of omega-3 fatty acids, today introduced to U.S. consumers Triomega(R) brand omega-3 supplements offering a high concentration of the most important omega-3 essential fatty acids in one daily softgel. Numerous clinical studies have been conducted on omega-3 intake, indicating omega-3 fatty acids offer health benefits to the heart, mind and joints.

Each Triomega softgel contains 800 mg of fish oil. The total EPA+DHA (eicosapentaenoic and docosahexaenoic acids, the most important essential fatty acids) content per softgel is 500 mg, offering approximately twice the concentration of most omega-3 supplements currently available in the U.S. market. The ratio of EPA to DHA is approximately 2:1, a balance that many experts believe is optimal for good health. This high concentration and optimal EPA to DHA ratio provide consumers the significant advantage and convenience of taking just one softgel per day.

The oil in Triomega is produced in a proprietary purification process that removes non-essential oils and results in a higher concentration of omega-3s. The process also removes many of the impurities and contaminants found in fatty fish and some other omega-3 supplements. Triomega supplements are manufactured in an FDA approved GMP (good manufacturing process) facility, ensuring quality and compliance with international standards for both the oil and the finished product.

Recognizing that consumers are often confused by unclear supplement labels, Triomega has designed the label and product packaging to clearly state the content of each softgel, including the percentage of the most important components, EPA and DHA.

Optimal Balance for Greatest Health Benefits

"Clinical studies and epidemiological research has shown that omega-3 fatty acids, which cannot be produced by the human body, are essential to the function and development of human cells. While evidence of an array of health benefits continues to emerge, research has demonstrated the positive effects of omega-3s to the heart, mind and joints," says Dr. Machelle Seibel, Medical Director at Inverness Medical. "For people with a low consumption rate of fatty fish, taking a daily omega-3 supplement can provide vital benefits to overall health and well-being."

While there is no formal Recommended Daily Allowance guideline for omega-3 intake, a statement issued in 2002 by the American Heart Association (AHA) recommends eating fish (particularly fatty fish) at least two times per week. Evidence from prospective secondary prevention studies suggests that amounts of EPA+DHA ranging from 0.5 grams to 1.8 grams per day, either as fatty fish or supplements, significantly reduce deaths from heart disease and other causes. Unlike most omega-3 supplements, which provide only 300 mg per softgel of EPA and DHA (requiring an individual to take two or more softgels per day), Triomega provides the AHA-recommended level of 500 mg in a highly concentrated single daily softgel.

"We are proud to introduce Triomega to U.S. consumers, providing a superior omega-3 supplement backed by extensive research and world leadership in marine omega-3 technology," said Egil Bodd, MD, PHD and Chief Executive Officer of Pronova Biocare. "American consumers demand quality products. At Pronova Biocare, our commitment to quality is manifested in the purity and concentration of our products. We recognize that safety, coupled with the convenience of a single daily dose, is the best way for us to help U.S. consumers achieve their health goals. We're confident that U.S. consumers will recognize Triomega's significant benefits over ordinary omega-3 supplements."

Triomega will be available in March of 2004 in drug, food and mass retailers, as well as in health food stores. Triomega will be packaged in both 30 and 60 count cartons in drug, food and mass, and in 45 and 90 count bottles in health food outlets. The Triomega brand of omega-3 supplements is distributed in the U.S. by Inverness Medical, Inc. of Waltham, MA.

About Triomega / Pronova Biocare

Pronova Biocare is a world leader in the development, manufacturing and sales of marine omega-3 fatty acids, with three omega-3 business units including consumer (Triomega(R), Pikasol(R) and Triomar(R)), pharmaceuticals (Omacor(R)) and industrial (EPAX(R)) brands. Triomega brand omega-3 supplements are currently available in the United States, Norway, Denmark, Sweden, Finland and Italy. For more information on Triomega, visit

About Inverness Medical, Inc.

Inverness Medical, Inc. manufactures, markets and sells a variety of products for the women's health and nutritional supplements markets. For more information on Inverness Medical, visit

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.